CANY
OLMA icon

Caxton Associates (New York)’s Olema Pharmaceuticals OLMA Stock Holding History

Caxton Associates (New York)’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,474
Closed -$166K – 517
2023
Q3 		$166K Buy
+13,474
New +$137K 0.02% 364

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caxton Associates (New York)'s OLMA Position: Q4 2023 in Review

Caxton Associates (New York) sold out of Olema Pharmaceuticals (OLMA) in Q4 2023, closing a stake of 13,474 shares — an estimated $166K sold.

Caxton Associates (New York) first reported a position in OLMA in Q3 2023 and held it in 1 quarter. The position peaked at $166K in Q3 2023. 113 funds tracked by Wall St. Rank hold OLMA as of Q4 2023.

  • Caxton Associates (New York) reported no remaining Olema Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 13,474 Olema Pharmaceuticals shares in Q4 2023, an estimated $166K.
  • Caxton Associates (New York) first reported a position in Olema Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Caxton Associates (New York)'s Olema Pharmaceuticals position peaked at $166K in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2023.

Based on Caxton Associates (New York)'s 13F filing for Q4 2023, filed 14 Feb 2024.